ArticleESMO open2018
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature.
Article in ESMO open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antibody-based regimens targeting PD-1/PD-L1 and VEGF/VEGFR in advanced or metastatic NSCLC: a meta-analysis of RCTs.Frontiers in immunology · 2026Pooled it
- First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.Journal for immunotherapy of cancer · 2024Trial
- Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma.JAMA network open · 2024Trial
- Efficacy and Safety of Initial Low-Dose, Extended-Interval Nivolumab Monotherapy in a 91-Year-Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report.Clinical case reports · 2026Article
- Clinical attribute-based risk matrix for prognostication in immunotherapy-treated non-small cell lung cancer.Nature communications · 2026Article
- Article
- Smoker's Lungs: Quo Vadis? Exploring the Shared and Individual Smoking-Related Molecular Pathways of Emphysema, Carcinoma, and Fibrosis - An Illustrative Review.Thoracic cancer · 2026Review
- Who Gets Left Out of Precision Oncology? Real-World Driver Mutation Expression Patterns and Therapeutic Eligibility in a Diverse Single-Center Early-Stage Lung Adenocarcinoma Cohort.Journal of racial and ethnic health disparities · 2026Article
- Evaluation of smoking status as a prognostic factor under immune checkpoint inhibitor treatment: A single center analysis.Oncology letters · 2026Article
- Factors influencing public willingness to participate in population-based hereditary cancer genetic testing: a qualitative study of public preferences.Familial cancer · 2026Article
- Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer.Journal for immunotherapy of cancer · 2025Article
- Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer.International journal of cancer · 2025Article
- Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.Oncology and therapy · 2025Article
- Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations.Translational lung cancer research · 2025Article
- Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC.Journal for immunotherapy of cancer · 2025Article
- Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.Nature reviews. Clinical oncology · 2025Review
- Outcomes with frontline immune checkpoint inhibitors among individuals withFrontiers in oncology · 2025Article
- A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy.Nature communications · 2024Article
- Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge.Biomedicines · 2024Article
- A Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%-90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed to review the knowledge in immunotherapy. PATIENTS AND
methodsA systematic review was done. We searched for documents and articles published in English language and registered in Cochrane Library, National Health Service (NHS) Centre for Reviews and Dissemination (CRD), Embase or Medline. The search terms were (A) (Lung cancer or NSCLC) with (pembrolizumab or nivolumab) with PD-L1 with (tobacco or smoking) and (B) Lung Neoplasms and Immunotherapy and (smoking cessation or patient compliance). 68 papers were detected and two more were added during review process (references) and six based on information from the manufacturers.
resultsNine papers were selected. High PD-L1 expression (≥50%) was correlated with current/ever smoking history in three studies. Six studies revealed a higher overall response rate (ORR) among current/former smokers. The ORR was generally (six studies) better among the current/former smoker group. So also when tumours had a molecular 'smoking signature' (one study). This was probably due to a higher mutational burden. In two studies, minor or no difference was revealed.One study (KEYNOTE-024) compared former and current smokers, and documented pembrolizumab being more effective among former smokers than current smokers.
conclusionsTobacco smoking patients with NSCLC generally have a higher PD-L1 tumour proportion score and experience a better ORR of immunotherapy than no smokers. There is little evidence on the effect of smoking during immunotherapy, but one study (KEYNOTE-024) may indicate survival gains of smoking cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.